Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Btissam ChamiMakoto OkudaMorvarid MoayeriFrançoise PirenneYoko HidakaAshok NambiarZhili SongOlivier BedelBailin ZhangJoern HopkeGejing DengChen ZhuSandrine MacéMarielle ChironFrancisco AdrianTaro FukaoFrank G BasileThomas MartinPublished in: Transfusion (2022)
Both isatuximab and daratumumab interfere with IATs but at different magnitudes, reflecting distinct binding to CD38 on RBCs. From the binding studies, we conclude that the isatuximab epitope on RBCs is masked in vitro and binding requires a certain CD38 conformation or co-factor. This circumstance may explain why interference is seen only in a subset of patients receiving isatuximab when compared with interference seen in most patients on daratumumab therapy.
Keyphrases
- monoclonal antibody
- multiple myeloma
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- high resolution
- nk cells
- prognostic factors
- peritoneal dialysis
- computed tomography
- magnetic resonance imaging
- dna binding
- stem cells
- molecular dynamics simulations
- magnetic resonance
- patient reported outcomes
- mesenchymal stem cells
- bone marrow
- crystal structure